Investigational Site Number :2030002

Brno 65691

2 studies enrolling now · 16 studies all time

What they study most

Breast Cancer, Breast Cancer Metastatic, Celiac Disease, Chronic Kidney Diseases, Coeliac Disease, Crohn's Disease, Cutaneous Lupus Erythematosus, Heart Failure, Hypercholesterolaemia, Non-relapsing Secondary Progressive Multiple Sclerosis, Plasma Cell Myeloma, Primary Progressive Multiple Sclerosis

Studies at this site

• A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease. — Recruiting now
• International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab — Enrolling by invitation
• A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant — Running, not enrolling
• A Phase 2a/b Study of the Efficacy and Safety of Subcutaneous Amlitelimab in Adults With Nonresponsive Celiac Disease — Running, not enrolling
• Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer — Stopped early
• A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis. — Running, not enrolling
• Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients — Completed
• Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS) — Completed
• Phase 1/2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer — Stopped early
• First-in-human Single Agent Study of SAR442085 in Relapsed or Refractory Multiple Myeloma — Completed
• Proof of Concept Study of SAR443122 in Patients With Cutaneous Lupus Erythematosus — Completed
• Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 2) — Completed
• Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (HERCULES) — Completed
• Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients — Completed
• An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia — Completed
• Effect of Sotagliflozin on Cardiovascular and Renal Events in Participants With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk — Stopped early